Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

Genetic evidence strongly supports the view that Aβ amyloid production is central to the cause of Alzheimer's disease. The kinetics, compartmentation, and form of Aβ and its temporal relation to the neurodegenerative process remain uncertain. The levels of soluble and insoluble Aβ were determined by using western blot techniques, and the findings were assessed in relation to indices of severity of disease. The mean level of soluble Aβ is increased threefold in Alzheimer's disease and correlates highly with markers of disease severity. In contrast, the level of insoluble Aβ (also a measure of total amyloid load) is found only to discriminate Alzheimer's disease from controls, and does not correlate with disease severity or numbers of amyloid plaques. These findings support the concept of several interacting pools of Aβ, that is, a large relatively static insoluble pool that is derived from a constantly turning over smaller soluble pool. The latter may exist in both intracellular and extracellular compartments, and contain the basic forms of Aβ that cause neurodegeneration. Reducing the levels of these soluble Aβ species by threefold to levels found in normal controls might prove to be a goal of future therapeutic intervention.

[1]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[2]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.

[3]  J. Trojanowski,et al.  The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging , 1999, Experimental Neurology.

[4]  Y. Ihara,et al.  Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging , 1999 .

[5]  P. Greengard,et al.  Generation and Regulation of β‐Amyloid Peptide Variants by Neurons , 1998 .

[6]  Y. Ihara,et al.  The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. , 1998, Biochemistry.

[7]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[8]  T. Iwatsubo,et al.  Mutant Presenilin 2 Transgenic Mouse: Effect on an Age‐Dependent Increase of Amyloid β‐Protein 42 in the Brain , 1998, Journal of neurochemistry.

[9]  K Namekata,et al.  Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. , 1998, The American journal of pathology.

[10]  R. Doms,et al.  Detection of a Novel Intraneuronal Pool of Insoluble Amyloid β Protein that Accumulates with Time in Culture , 1998, The Journal of cell biology.

[11]  Y. Ihara,et al.  Amyloid β-protein (Aβ) Accumulation in the Putamen and Mammillary Body during Aging and in Alzheimer Disease , 1998 .

[12]  M. Shoji,et al.  Biochemical heterogeneity of Alzheimer's disease , 1998 .

[13]  J. Price,et al.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.

[14]  B. Greenberg,et al.  Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester , 1998, The Journal of Neuroscience.

[15]  A. Roses Apolipoprotein E, a Gene with Complex Biological Interactions in the Aging Brain , 1997, Neurobiology of Disease.

[16]  Yasuo Ihara,et al.  Amyloid β‐protein deposition in the leptomeninges and cerebral cortex , 1997 .

[17]  C. Duyckaerts,et al.  Diagnosis and Staging of Alzheimer Disease , 1997, Neurobiology of Aging.

[18]  C. Masters,et al.  Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Dickson,et al.  The Pathogenesis of Senile Plaques , 1997, Journal of neuropathology and experimental neurology.

[20]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[21]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[22]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[23]  L. Forno,et al.  P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. , 1996, The American journal of pathology.

[24]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[25]  D. Mann,et al.  Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.

[26]  S. Hirai,et al.  Modified Amyloid β Protein Ending at 42 or 40 with Different Solubility Accumulates in the Brain of Alzheimer′s Disease , 1995 .

[27]  W. Honer,et al.  Correlations of synaptic and pathological markers with cognition of the elderly , 1995, Neurobiology of Aging.

[28]  N. Suzuki,et al.  Biochemical evidence for the long-tail form (Aβ1-42/43) of amyloid β protein as a seed molecule in cerebral deposits of alzheimer′s disease , 1994 .

[29]  M. Tabaton,et al.  Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. , 1994, Biochemical and biophysical research communications.

[30]  M. Ball,et al.  Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.

[31]  B. Hyman,et al.  The Lack of Accumulation of Senile Plaques or Amyloid Burden in Alzheimer's Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution , 1993, Journal of neuropathology and experimental neurology.

[32]  D. Selkoe,et al.  beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. , 1993, The Journal of biological chemistry.

[33]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[34]  B. Hyman,et al.  Amyloid, dementia and Alzheimer's disease. , 1992, Current opinion in neurology and neurosurgery.

[35]  K. Kosik,et al.  Neuritic pathology and dementia in alzheimer's disease , 1991, Annals of neurology.

[36]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[37]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[38]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .